Related Experiment Video
Updated: Jun 10, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
[A new clinical classification of pulmonary hypertension]
1Université Paris-Sud 11, UPRES EA 2705, Centre National de Référence de l'Hypertension Artérielle Pulmonaire, Pneumologie et Réanimation respiratoire, Hôpital Antoine Béclère, 157, rue de la Porte de Trivaux 92141 Clermont cedex, France. gerald.simonneau@abc.aphp.fr
Abstract:
The classification of pulmonary hypertension (PHT) has undergone a series of changes since first published in 1973. The initial classification recognized only two categories: primary pulmonary hypertension and secondary pulmonary hypertension, depending on the presence or absence of identified causes or risk factors. In 2008, at the 4th world symposium on PHT at Dana Point (California, USA), an international expert group agreed on the need to revise the previous classifications in order to take into account findings published in the last five years and to clear up certain ambiguities.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure IV: Classification and Diagnostic Evaluation
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

